ASSESSING THE HIV-1 VIRAL RESERVOIR IN TISSUE SAMPLES

ASSESSING THE HIV-1 VIRAL RESERVOIR IN TISSUE SAMPLES
Recruiting
18-99 years
All
Phase N/A
100 participants needed
1 Location

Brief description of study

Treating HIV infection with antiretroviral therapy (ART) leads to control of the virus and improvement of the immune system, which is your body natural ability to fight diseases.
HIV patients who are well controlled (undetectable HIV by blood tests) still have HIV virus which hides deep in their body’s tissues (HIV reservoir) and is not completely eliminated. The purpose of this study is to better understand the nature of this HIV reservoir and to study strategies to eliminate it in the laboratory.

This protocol involves the collection of rectal tissue samples from HIV-1 infected individuals to evaluate strategies to decrease or target the latent reservoir using an ex vivo models and to evaluate the size and different measurement methodologies of the HIV reservoir. Tissue collections (i.e., 6-16 specimens per collection) via rectal biopsy for use in basic science work.

Detailed description of study

If you agree to join the study, there will be two visits at Penn Presbyterian Medical Center or Perelman Center for Advance Medicine (PCAM). During the first visit we will discuss the study in detail prior to signing the study consent.  Information will be collected about your medical history (your current medical conditions, medications, and lab results) in order to evaluate whether you can safely participate in this tissue collection study.  At the second study visit tissue samples from your rectal mucosa (the lining of your gut) will be collected via a rectal biopsy by a specially trained doctor.  The rectal biopsy procedure is performed without sedation and is generally well tolerated by participants.  Your study participation will last over a period of approximately 1 month. You will be compensated for each study visit.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: HIV
  • Age: Between 18 Years - 99 Years
  • Gender: All


Updated on 01 Aug 2024. Study ID: 834367

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center